MX2022007516A - Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos. - Google Patents

Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.

Info

Publication number
MX2022007516A
MX2022007516A MX2022007516A MX2022007516A MX2022007516A MX 2022007516 A MX2022007516 A MX 2022007516A MX 2022007516 A MX2022007516 A MX 2022007516A MX 2022007516 A MX2022007516 A MX 2022007516A MX 2022007516 A MX2022007516 A MX 2022007516A
Authority
MX
Mexico
Prior art keywords
antagonist
methods
treating cancer
chemotherapeutic agents
ilt4
Prior art date
Application number
MX2022007516A
Other languages
English (en)
Inventor
Rachel A Altura
Philip E Brandish
Bilal Piperdi
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2022007516A publication Critical patent/MX2022007516A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se proporcionan métodos para tratar el cáncer (por ejemplo, NSCLC), que comprenden administrar a un paciente humano que lo necesite: (a) un antagonista de PD-1; (b) un antagonista de ILT4; y (c) uno o más agentes quimioterapéuticos; también se proporcionan composiciones farmacéuticas y kits que contienen dichos agentes para el tratamiento del cáncer.
MX2022007516A 2019-12-20 2020-12-16 Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos. MX2022007516A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951357P 2019-12-20 2019-12-20
PCT/US2020/065208 WO2021126906A1 (en) 2019-12-20 2020-12-16 Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MX2022007516A true MX2022007516A (es) 2022-07-05

Family

ID=76476667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007516A MX2022007516A (es) 2019-12-20 2020-12-16 Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.

Country Status (10)

Country Link
US (1) US20230050449A1 (es)
EP (1) EP4076521A4 (es)
JP (1) JP2023510132A (es)
KR (1) KR20220123017A (es)
CN (1) CN115087461A (es)
AU (1) AU2020408678A1 (es)
BR (1) BR112022012081A2 (es)
CA (1) CA3162311A1 (es)
MX (1) MX2022007516A (es)
WO (1) WO2021126906A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4373857A1 (en) * 2021-07-20 2024-05-29 Merck Sharp & Dohme LLC Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
WO2024120526A1 (zh) * 2022-12-09 2024-06-13 诺纳生物（苏州）有限公司 抗ilt4抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230144099A (ko) * 2014-05-15 2023-10-13 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
EP3858859A1 (en) * 2015-07-14 2021-08-04 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
CN111712255A (zh) * 2018-02-13 2020-09-25 默沙东公司 用抗pd-1抗体治疗癌症的方法
MX2022008216A (es) * 2020-01-02 2022-08-04 Merck Sharp & Dohme Llc Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.

Also Published As

Publication number Publication date
BR112022012081A2 (pt) 2022-08-30
CA3162311A1 (en) 2021-06-24
WO2021126906A1 (en) 2021-06-24
JP2023510132A (ja) 2023-03-13
US20230050449A1 (en) 2023-02-16
KR20220123017A (ko) 2022-09-05
CN115087461A (zh) 2022-09-20
EP4076521A4 (en) 2024-01-24
EP4076521A1 (en) 2022-10-26
AU2020408678A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
SG10201902664RA (en) Combination therapy for treating cancer
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
MX2020011817A (es) Metodos para tratar el linfoma.
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
PH12020500666A1 (en) Pladienolide compounds and their use
MX2019013862A (es) Terapia de combinacion.
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2021008941A (es) Moduladores gpr35.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
BR112021016923A2 (pt) Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
MX2024001892A (es) Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.